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Abstract
Background: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ 
burden of interference with activities of daily living, and HZ impact on quality of life.
Methods: The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of 
illness and HZ burden of interference with activities of daily living were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument and 
quality of life by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled 
analysis of patients aged 70 years and older from the trials combined.
Results: The estimated vaccine efficacy in reducing HZ burden of illness and HZ burden of interference was greater than 90% in both the 
ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, adjuvanted recombinant zoster vaccine reduced the maximal ZBPI worst-
pain score in the pooled ZOE-70 analysis (p = .032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p = .049) and the pooled 
ZOE-70 analysis (p = .043). In breakthrough HZ cases, trends for diminished loss of quality of life compared with placebo-recipient HZ cases 
were observed, with differences up to 0.14 on the EQ-5D index at time points during the 4 weeks following HZ onset.
Conclusions: Adjuvanted recombinant zoster vaccine reduced the HZ burden of illness significantly, particularly due to its very high vaccine 
efficacy in preventing HZ. For breakthrough HZ cases, the results suggest that the adjuvanted recombinant zoster vaccine mitigated severity 
of HZ-related pain, burden of interference with activities of daily living, and recipients’ utility loss.
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Herpes zoster (HZ) results from reactivation of the varicella-zoster 
virus (VZV). HZ typically manifests as a unilateral, painful der-
matomal rash. Most cases of HZ resolve completely within about 
1 month of rash onset, but 10%–20% of HZ patients develop post-
herpetic neuralgia, a condition of debilitating pain that may last for 
months or even years and is very difficult to treat (1–3).
The pain and discomfort experienced during an acute HZ epi-
sode may substantially reduce patients’ health-related quality of life 
(QoL) by impairing their physical, emotional, and social function-
ing. The pain may interfere with patients’ ability to perform activi-
ties of daily living (ADLs), diminish vitality, and impair physical and 
mental health (4–6).
The incidence of HZ increases substantially from around the 
age of 50  years, concurrent with the natural age-related decline 
of cell-mediated immunity, which is considered an important risk 
factor for reactivation of VZV (7). The lifetime risk of developing 
HZ is estimated at approximately 30%, increasing to 50% or more 
in people living beyond the age of 85 years (8,9).
The principal available treatments for HZ, analgesics, and anti-
virals have shown efficacy in the context of clinical trials but in clin-
ical-practice patient satisfaction with their perceived effectiveness in 
alleviating symptoms was found to be low (9). HZ is preventable by 
vaccination, and an HZ vaccine containing live attenuated VZV was 
licensed in the United States and Europe in 2006 (10).
Adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) is 
a two-dose adjuvanted nonlive subunit vaccine combining recom-
binant VZV glycoprotein E and the AS01B adjuvant system. Two 
multinational Phase III randomized, observer-blinded, placebo-
controlled clinical trials were conducted concurrently at the same 
study sites using the same methods to assess the efficacy of RZV 
in preventing HZ in two adult populations. The ZOE-50 study 
(NCT01165177) included patients aged 50 years and older (11) and 
ZOE-70 study (NCT01165229) included patients aged 70 years and 
older (12). For patients developing HZ, the trials also collected data 
for assessing the burden of illness of HZ, its burden of interference 
with the patients’ ADLs and its impact on their QoL.
A protocol prespecified pooled analysis of all patients aged 
70  years and older from the two trials (henceforth “the pooled 
ZOE-70 analysis”) was performed to obtain more robust estimates 
of the vaccine’s efficacy in people aged 70 years and older. In both 
the ZOE-50 trial and the pooled ZOE-70 analysis, the overall vac-
cine efficacy (VE) of RZV in preventing HZ was estimated to be 
more than 90% (11,12).
In this article, using data from the ZOE study and the pooled 
ZOE-70 analysis, we present results showing the efficacy of RZV in 
preventing the burden of illness of HZ and the HZ burden of inter-
ference with ADLs, and its impact on the QoL of patients with HZ. 
The corresponding comparative results of the ZOE-70 analysis are 
presented in Supplementary Material for this article.
Methods
Study Design
The study design was described in detail in the articles presenting the 
efficacy and safety results of the trials (11,12).
Outcome Measures
Patients with suspected HZ were asked to attend assessment vis-
its and to complete the Zoster Brief Pain Inventory (ZBPI) daily 
for 28  days after rash onset and then weekly until either the pa-
tient had been pain free for four consecutive weeks or 90 days had 
elapsed after rash onset (whichever came last). For all analyses of 
data involving HZ episodes, Day 0 was defined as the first day of 
HZ rash (13). If the rash had started more than 24 hours before the 
initial assessment, patients were asked to retrospectively complete 
the ZBPI for the period between rash onset and 24 hours before the 
first assessment day.
The ZBPI asks the patients to rate four categories of pain (least, 
worst, average over the last 24 hours, and now) on 11-point Likert-
type scales (0–10, with 10 signifying the worst imaginable pain). The 
“worst pain” over the last 24 hours category is considered the most 
reliable indicator of pain (13) and was used to measure the VE in 
reducing the burden of illness related to HZ pain.
The ZBPI questionnaire also assesses the degree to which the 
HZ pain interferes with seven ADLs: general activity, mood, walk-
ing ability, work, relation with others, sleep, and enjoyment of 
life. These are all to be rated on 11-point Likert-type scales with 
Table 1. HZ ZBPI Severity and Burden of Illness Scores (Based on ZBPI “Worst-Pain” Score)
Age Group 
(YOA)
RZV Placebo
VE (%)
95% CI for 
VE (%)n m
ZBPI Severity of 
Illness Scorea
ZBPI Burden of 
Illness Score n m
ZBPI Severity of 
Illness Scorea
ZBPI Burden of 
Illness Score
ZOE-50 study
 50–59 4 3,491 0.069 0.018 103 3,523 4.179 1.056 98.3 (83.8, 100)
 60–69 3 2,140 0.082 0.020 89 2,165 4.274 1.067 98.1 (79.2, 100)
 ≥70 2 1,709 0.069 0.019 60 1,723 6.059 1.644 98.9 (72.1, 100)
 Total 9 7,340 0.073 0.019 252 7,411 4.644 1.188 98.4 (92.2, 100)
Pooled ZOE-70 analysis
 70–79 19 6,468 0.316 0.084 214 6,552 6.369 1.690 95.1 (92.5, 97.7)
 ≥80 6 1,782 1.222 0.344 67 1,791 6.777 1.932 82.2 (77.2, 87.2)
 Total 25 8,250 0.511 0.137 281 8,343 6.457 1.739 92.1 (90.4, 93.8)
Notes: CI = confidence interval; HZ = herpes zoster; m = total number of patients in this group; n = number of HZ cases in this group; RZV = adjuvanted recom-
binant zoster vaccine; VE = vaccine efficacy; YOA = years of age; ZBPI = Zoster Brief Pain Inventory.
aZBPI severity of illness was calculated as the area under the curve (AUC), Days 0–182, of the ZBPI “worst-pain” score for patients with confirmed HZ cases. 
Patients without a confirmed HZ case were allocated an AUC score of 0. The ZBPI burden of illness score was calculated as the ZBPI severity of illness score 
divided by the total follow-up in years. In the ZOE-50 study and pooled ZOE-70 analysis, two and three patients in the placebo groups, respectively, had a con-
firmed HZ episode but did not have an evaluable ZBPI score and were therefore not included in this table. Score: 0–10, with 10 signifying the worst pain.
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0 signifying “does not interfere” and 10  “completely interferes.” 
A summary ADL score is calculated by averaging the scores for the 
seven activities.
The EuroQol-5 Dimension (EQ-5D) is a utility instrument widely 
used in assessments of individuals’ health-related QoL. Patients are 
asked to grade their extent of problems (no problem, some prob-
lems, and severe problems) in five dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. The com-
bination of answers to the five dimensions results in 243 possible 
health states, each of which may be translated into a utility score 
ranging from less than 0 (ie, a health state worse than death) to 1 (ie, 
best possible health state) (14).
QoL was also assessed by the Short Form Survey (SF-36) 
(15). This assessment method and a short summary of the SF-36 
results are described in Supplementary Material for this article. All 
patients were asked to complete the EQ-5D and SF-36 question-
naires at baseline (ie, Day 0, before vaccination Dose 1). Patients 
not developing HZ were asked to complete the questionnaires at 
Months 14, 26, and 38. All patients experiencing a suspected HZ 
episode were to complete both the EQ-5D and SF-36 at the first 
visit to evaluate suspected HZ and then weekly along with the 
ZBPI.
For patients with suspected HZ, specimens were tested cen-
trally by polymerase chain reaction and reviewed by an adjudi-
cation committee. Only HZ cases confirmed by polymerase chain 
reaction or by the adjudication committee were included in the 
analyses (11,12).
Statistical Analyses
For each case of HZ, the maximal ZBPI “worst-pain” and “average-
pain” scores during the HZ episode were calculated and compared 
between the RZV and placebo groups by means of the Wilcoxon 
nonparametric test. Clinically significant pain was defined as a ZBPI 
“worst-pain” score greater than or equal to 3.
A combined measure of pain intensity and duration was calcu-
lated by the area under the curve method (13). For each patient, 
the area under the curve was calculated by multiplying the average 
of two consecutive ZBPI worst-pain scores by the number of days 
between the scores and adding up these measures over a specified 
time period (13). The modified ZBPI scale was used (13), which 
from Day 30 onwards sets ZBPI “worst-pain” scores of less than 
3 equal to 0. The ZBPI severity of illness scores were calculated 
as the area under the curve from the day of rash onset until Day 
182. An area under the curve value of 0 was imputed for patients 
without confirmed HZ. The burden of illness due to pain was then 
estimated by aggregating the severity of illness scores over all the 
Table 2. HZ ZBPI Severity and Burden of Interference Scores (Based on ZBPI ADL Summary Scores)
Age Group 
(YOA)
RZV Placebo
VE
95% CI for 
VEn m
ZBPI Severity of 
Interference Scorea
ZBPI Burden of 
Interference Score n m
ZBPI Severity of 
Interference Scorea
ZBPI Burden of 
Interference Score
ZOE-50 study
 50–59 4 3,491 0.024 0.006 103 3,523 2.850 0.720 99.2 (68.0, 100)
 60–69 3 2,140 0.038 0.010 89 2,165 2.823 0.705 98.7 (63.8, 100)
 ≥70 2 1,709 0.024 0.006 60 1,723 4.004 1.087 99.4 (37.0, 100)
 Total 9 7,340 0.028 0.007 252 7,411 3.110 0.796 99.1 (86.2, 100)
Pooled ZOE-70 analysis
 70–79 19 6,468 0.180 0.048 214 6,552 4.261 1.130 95.8 (92.3, 99.3)
 ≥80 6 1,782 1.353 0.381 67 1,791 5.110 1.457 73.8 (69.5, 78.1)
 Total 25 8,250 0.434 0.116 281 8,343 4.443 1.196 90.3 (88.5, 92.1)
Notes: ADL = activities of daily living; CI = confidence interval; HZ = herpes zoster; m = total number of patients in this group; n = number of HZ cases in this 
group; VE = vaccine efficacy; YOA = years of age; ZBPI = Zoster Brief Pain Inventory.
aZBPI severity of interference was calculated as the area under the curve (AUC), Days 0–182, of the ZBPI ADL score for patients with confirmed HZ cases. 
Patients without a confirmed HZ case were allocated an AUC score of 0. The ZBPI burden of interference score was calculated as the ZBPI severity of interference 
score divided by the total number of years of follow-up. Score: 0–10, with 0 signifying “does not interfere” and 10 “completely interferes.”
Figure  1. Mean ZBPI “worst-pain” scores per day during the first 
28  days after rash onset (A: ZOE-50 study; B: pooled ZOE-70 analysis). 
RZV  =  adjuvanted  recombinant zoster vaccine; ZBPI  =  Zoster Brief Pain 
Inventory. *Days with statistically significant differences (at the .05 level) in 
ZBPI worst-pain scores between the two groups. In the ZOE-50 study, no RZV 
recipient with HZ completed the ZBPI days 0 and 1.
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patients in a group and dividing by the total number of years of 
patient follow-up. Consequently, this composite measure takes the 
incidence of HZ as well as the severity and duration of HZ pain 
into account.
VE was defined as the relative reduction in the burden of illness 
score in the RZV group as compared to the score in the placebo 
group and calculated as 1 minus the relative risk (ie, the burden of 
illness score in the RZV group divided by the burden of illness score 
in the placebo group). The VE in reducing the burden of interfer-
ence was defined and calculated in a similar way using the combined 
ZBPI ADL score as the measure.
These analyses were performed on the modified total vaccinated 
cohort, which excluded patients who did not receive two doses or 
who had a confirmed HZ episode within 1 month of receiving Dose 
2 and included only HZ patients who completed at least one ZBPI 
questionnaire. The chop-lump test (16) was used to assess the differ-
ence in ZBPI severity of illness scores and ZBPI severity of interfer-
ence scores between the RZV and placebo groups in the modified 
total vaccinated cohort.
In a post hoc analysis, VE for reducing severe ZBPI pain 
(score ≥ 7 for “worst-pain”) was estimated in patients in the modi-
fied total vaccinated cohort HZ evaluable subgroup which included 
confirmed HZ cases with a ZBPI questionnaire completed during 
the first 14 days after HZ onset. Standardized asymptotic binomial 
confidence intervals (CI) for the VE were calculated using the score 
method of Farrington and Manning (17).
A repeated-measures analysis of variance model was fitted to 
estimate the impact of HZ on EQ-5D utility scores in the placebo 
group only, stratified by age. There were too few patients in the RZV 
group with breakthrough HZ to apply this modeling approach. The 
model included the baseline utility scores, that is, the most recent 
utility assessment prior to the onset of HZ and the utility scores 
during the first 4 weeks of the HZ episode. The least squares mean 
estimates over time are presented.
Results
Flowcharts of the trials and demographic data of the patients 
enrolled in the two studies who developed confirmed HZ along 
with the various study populations are presented in Supplementary 
Figures S1 and S2. At the end of study analysis of the ZOE-50 study, 
9 HZ cases had occurred among the 7,340 patients receiving RZV 
compared with 254 cases among the 7,413 patients receiving pla-
cebo. In the pooled ZOE-70 analysis, 25 HZ cases occurred among 
the 8,250 patients receiving RZV and 284 cases among the 8,346 
patients receiving placebo (Table 1).
Table 3. Distribution of Maximal ZBPI “Worst-Pain” and ZBPI “Average-Pain” Scores Over the Duration of the Entire HZ Episode
ZBPI Scale
ZOE-50 Pooled ZOE-70
RZV (N = 8) Placebo (N = 241)
p Value
RZV (N = 23) Placebo (N = 263)
p Valuen (%) n (%) n (%) n (%)
“Worst-pain” score
 ≥3 7 (87.5) 211 (87.6) .113 19 (82.6) 239 (90.9) .032
 0 1 (12.5) 13 (5.4) 1 (4.3) 18 (6.8)
 1 0 10 (4.1) 1 (4.3) 2 (0.8)
 2 0 7 (2.9) 2 (8.7) 4 (1.5)
 3 0 9 (3.7) 1 (4.3) 21 (8.0)
 4 2 (25.0) 13 (5.4) 4 (17.4) 14 (5.3)
 5 0 19 (7.9) 2 (8.7) 16 (6.1)
 6 1 (12.5) 13 (5.4) 2 (8.7) 8 (3.0)
 7 2 (25.0) 33 (13.7) 1 (4.3) 23 (8.7)
 8 2 (25.0) 38 (15.8) 3 (13.0) 50 (19.0)
 9 0 48 (19.9) 5 (21.7) 43 (16.3)
 10 0 38 (15.8) 1 (4.3) 64 (24.3)
 Mean 5.5 6.7 5.7 7.0
 SD 2.73 2.94 2.96 3.02
“Average-pain” score
 0 1 (12.5) 14 (5.8) .049 1 (4.3) 19 (7.2) .043
 1 0 13 (5.4) 2 (8.7) 8 (3.0)
 2 0 15 (6.2) 2 (8.7) 18 (6.8)
 3 2 (25.0) 13 (5.4) 4 (17.4) 18 (6.8)
 4 1 (12.5) 25 (10.4) 2 (8.7) 21 (8.0)
 5 3 (37.5) 23 (9.5) 3 (13.0) 26 (9.9)
 6 1 (12.5) 40 (16.6) 4 (17.4) 35 (13.3)
 7 0 30 (12.4) 3 (13.0) 46 (17.5)
 8 0 38 (15.8) 1 (4.3) 32 (12.2)
 9 0 17 (7.1) 0 21 (8.0)
 10 0 13 (5.4) 1 (4.3) 19 (7.2)
 Mean 3.9 5.5 4.5 5.6
 SD 1.89 2.74 2.50 2.81
Notes: HZ = herpes zoster; N = number of HZ cases in each group; n = number of HZ cases in each category; ZBPI = Zoster Brief Pain Inventory. Includes 
only patients in the modified total vaccinated cohort HZ evaluable subgroup, that is, confirmed HZ cases with a ZBPI questionnaire completed during the first 
14 days after HZ onset.
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The mean delay between the date of rash onset and the first HZ 
evaluation was 4.7 and 4.8 days in the ZOE-50 and pooled ZOE-
70 analysis, respectively (range 0–33 in both analyses). Completion 
rates for the ZBPI questionnaire were approximately 15% on Day 
0, more than 60% from Day 3 onwards, and greater than or equal 
to 80% from Day 6 onwards. For the EQ-5D and SF-36 instruments 
during an ongoing HZ episode, the completion rates were approxi-
mately 50% on Day 0 and greater than or equal to 84% at all time 
points thereafter.
Overall VE
The estimated overall VE in reducing the ZBPI burden of illness 
was 98.4% in the ZOE-50 study and 92.1% in the pooled ZOE-70 
analysis (Table 1). The VE in reducing burden of illness was lower in 
patients aged 80 years and older (ie, 82.2%). However, the absolute 
reduction in burden of illness score was higher in these patients com-
pared with younger patients (ie, 1.932–0.344 ≈ 1.6 in patients aged 
80 years and older compared with 1.0 in patients aged 50–69 years). 
The estimated overall VE in reducing the burden of interference with 
ADLs was 99.1% in the ZOE-50 study and 90.3% in the pooled 
ZOE-70 analysis (Table 2).
Outcomes for Patients Developing HZ
Figure 1 presents the mean ZBPI “worst-pain” scores per day during 
the first 28 days for all the confirmed HZ cases. The mean “worst-
pain” scores were at all times lower in the RZV group than in the 
placebo group, but the differences were only statistically significant 
for a few days spread over the period in the pooled ZOE-70 analysis.
Table 3 presents the distribution of the individual maximal ZBPI 
“worst-pain” and “average-pain” scores experienced over the entire 
HZ episode. In the ZOE-50 study, a severe ZBPI “worst-pain” score 
(ie, ≥7) was reported by 50.0% in the RZV group and 65.2% in the 
placebo group (VE 23.3%, 95% CI  =  −22.4%–67.2%). The cor-
responding proportions reporting severe ZBPI “average pain” were 
0% and 40.7%, respectively (VE 100%, 95% CI = 19.4%–100%). 
The median time to resolution of clinically significant pain (ie, ZBPI 
“worst pain” ≥ 3) was 14 days in the RZV group and 17 days in the 
placebo group (p = .600).
In the pooled ZOE-70 analysis, the proportions reporting severe 
“worst pain” were 43.5% in the RZV group and 68.4% in the pla-
cebo group (VE 36.5%, 95% CI = 6.5%–62.8%). The correspond-
ing proportions reporting severe “average pain” were 21.7% in 
the RZV group and 44.9% in the placebo group (VE 51.6%, 95% 
CI = 4.9%–78.7%). The median time to resolution of clinically sig-
nificant pain was 14 days in the RZV group versus 22 days in the 
placebo group (p = .409).
Figure 2 presents the mean ZBPI ADL interference scores during 
the first 28 days for the placebo groups only. Sleep, mood, and gen-
eral activities appear to be the most affected. In both plots, the mean 
ADL interference scores appeared to peak at Days 3 and 4 after rash 
onset and gradually diminished over time.
Table 4 presents the utility loss of the HZ patients in the pla-
cebo groups over the first 28 days after rash onset, assessed using the 
EQ-5D instrument. The estimated utility loss was highest on Day 0 
and decreased over time in all age groups as the patients recovered 
from HZ, but a negative impact of HZ on QoL remained until the 
end of Week 4.
The estimated differences over time in mean EQ-5D utility scores 
between the RZV and placebo groups are presented in Figure 3, sug-
gesting that they were greatest at Day 0 (up to 0.14 in ZOE-50) and 
decreased over time. Using the utility assessments prior to the HZ 
episode as baseline, the VE in terms of reducing the patients’ utility 
loss due to HZ over the first 28 days after rash onset was estimated 
to be 63.7% in the ZOE-50 study and 21.2% in the pooled ZOE-70 
analysis.
Discussion
The overall efficacy of the RZV in reducing the burden of illness 
and the burden of interference in ADLs of HZ was more than 
90% in both the ZOE-50 study and the pooled ZOE-70 analysis. 
These are mainly the results of VE in preventing HZ. However, 
even with the small number of breakthrough HZ cases compared 
with the placebo recipients, this study demonstrated that adults 
who developed HZ despite vaccination with RZV were less likely 
to have severe pain, and there was a trend for them to have a 
shorter duration of pain, less burden of interference in ADLs, and 
higher QoL scores over the first 4 weeks following rash onset. 
Therefore, RZV not only prevented HZ but also attenuated the 
severity of disease in individuals who developed HZ despite being 
vaccinated with RZV.
The corresponding comparative results of the ZOE-70 analysis 
are presented in Supplementary Material for this article. The results 
are in line with the ZOE-70 pooled analysis presented in the main 
text and also with those presented by Cunningham and colleagues 
(12). Note that the two clinical trials, ZOE-50 and ZOE-70, were 
conducted at the same sites, and patients aged 70 years and older 
were randomly assigned to the ZOE-50 or ZOE-70 study. This 
ensured that the prespecified pooled analysis could be done appro-
priately, leading to more robust results in all patients aged 70 years 
and older.
Figure  2. Mean daily ZBPI ADL scores during the first 28  days after rash 
onset for the placebo groups (A: ZOE-50 study; B: pooled ZOE-70 analysis). 
ADL = activities of daily living; ZBPI = Zoster Brief Pain Inventory.
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It is likely that vaccine-induced VZV-specific CD4+ T cells play a 
role in the attenuation of breakthrough cases for both the live attenu-
ated vaccine and for RZV (especially as such CD4+ T cells are pre-
sent in the dorsal root ganglion in natural HZ). Plausible hypotheses 
are that memory CD4+ T cells could have direct antiviral effects (eg, 
through interferon-γ) or could mobilize natural killer cells, resulting 
in (antibody-dependent) cytolytic responses. Thus, memory CD4+ T 
cells would be capable of mounting a rapid antiviral response upon 
reactivation of VZV. In some cases, this anamnestic immune response 
may not be able to prevent an HZ episode, but in vaccine recipients 
with breakthrough disease, the response may be sufficient to more rap-
idly control the reactivated virus, leading to reduced severity of disease. 
Observations of apparent mitigation of breakthrough disease in vac-
cine recipients have also been reported for a number of other vaccine-
preventable diseases such as influenza, rotavirus, and pertussis (18–20).
The greatest interference of HZ-related pain on ADLs occurred 
during the first week following rash onset. Sleep was the most 
impacted activity in the placebo recipients. Another study also found 
that some 65% of HZ patients did not get sufficient sleep most of 
the time (21). As both the ZBPI pain and ADL interference scores 
on the day of rash onset were high, it may be hypothesized that pain 
started during the prodromal period. Previous studies showing that 
prodromal pain may last for 1–5 days or even longer before rash 
onset (6,22) suggest that the overall duration of clinically relevant 
HZ pain and utility loss was greater than we estimated.
In the placebo groups, based on the mean utility values estimated 
for the HZ patients during the first 4 weeks after HZ onset (Table 4) 
and the pre-HZ scores, the monthly values for the utility loss may be 
estimated at 0.140 and 0.132 (ie, 4.3 and 4.0 days of perfect health 
lost for each month of HZ) for the ZOE-50 and pooled ZOE-70 
analysis, respectively. These values are in line with Pellissier and col-
leagues (23), who also reported quality-adjusted life-years losses for 
postherpetic neuralgia patients, in unvaccinated patients of 0.106 
and 0.156 (ie, 38.7 and 56.9 days of perfect health lost during a 
year). Kawai and colleagues, in a literature review, estimated, based 
on the values from Pellissier and colleagues, that the overall quality-
adjusted life-years lost due to HZ including postherpetic neuralgia 
was 0.021, 0.049, and 0.058 for patients aged 60–69, 70–79, and 
80 years and older, respectively. Much higher values were reported 
by Moore and colleagues based on data from Oster and colleagues 
(1,24,25). Using these estimates and incidence estimates from Leung 
and colleagues (26), between 25,000 and 100,000 years of perfect 
health are lost annually in the United States in patients aged 60 years 
and older due to HZ.
As a consequence of the high VE against HZ, and the low 
number of breakthrough cases, the statistical power to identify stat-
istically significant differences between the groups is low. We calcu-
lated, using Cohen’s “d” effect size measure, that at the p = .05 level, 
power was only 29% for the ZOE-50 study and 63% for the pooled 
ZOE-70 analysis (27).
Table 4. Estimated Placebo-Group EQ-5D Scores for Utility Loss by Age Group and Time Point During the Acute HZ Period
Age Group (YOA) Time Point LS Means Estimate Estimated Utility Loss 95% CI
ZOE-50 study
 50–59 Pre-HZ 0.880
Day 0 0.622 0.258 (0.204, 0.313)
Week 1 0.685 0.195 (0.136, 0.254)
Week 2 0.736 0.145 (0.081, 0.208)
Week 3 0.821 0.059 (−0.007, 0.125)
Week 4 0.872 0.008 (−0.060, 0.076)
 60–69 Pre-HZ 0.879
Day 0 0.637 0.242 (0.176, 0.308)
Week 1 0.713 0.166 (0.102, 0.230)
Week 2 0.791 0.087 (0.020, 0.155)
Week 3 0.800 0.078 (0.008, 0.150)
Week 4 0.799 0.080 (0.007, 0.152)
 ≥70 Pre-HZ 0.800
Day 0 0.517 0.284 (0.209, 0.358)
Week 1 0.610 0.190 (0.110, 0.270)
Week 2 0.703 0.097 (0.011, 0.184)
Week 3 0.713 0.087 (0.000, 0.175)
Week 4 0.765 0.035 (−0.054, 0.124)
Pooled ZOE-70 analysis
 70–79 Pre-HZ 0.840
Day 0 0.606 0.234 (0.191, 0.277)
Week 1 0.674 0.166 (0.121, 0.210)
Week 2 0.686 0.153 (0.107, 0.200)
Week 3 0.735 0.105 (0.057, 0.152)
Week 4 0.787 0.052 (0.004, 0.100)
 ≥80 Pre-HZ 0.753
Day 0 0.542 0.211 (0.133, 0.289)
Week 1 0.645 0.108 (0.030, 0.187)
Week 2 0.686 0.067 (−0.017, 0.150)
Week 3 0.682 0.071 (−0.015, 0.157)
Week 4 0.749 0.004 (−0.083, 0.091)
Notes: CI = confidence interval; EQ-5D = EuroQol-5 Dimension; HZ = herpes zoster; LS = least squares; YOA = years of age. An EQ-5D value of 1 represents 
the best possible health state.
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To conclude, this study provided evidence that the RZV vaccine, 
in addition to its very high efficacy in preventing HZ, has an effect 
of attenuating the severity of HZ disease in breakthrough cases. This 
mitigation was most clearly quantified with the HZ-specific ZBPI 
instrument to assess the severity of pain but was also discernible as 
trends with the less sensitive, generic QoL instruments. Vaccination 
with RZV could prevent loss of quality of life associated with both 
HZ and postherpetic neuralgia.
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